PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPrasugrel
Effient, Efient(prasugrel)
Effient, Efient, Prasugrel (prasugrel) is a small molecule pharmaceutical. Prasugrel was first approved as Efient on 2009-02-24. It has been approved in Europe to treat acute coronary syndrome, myocardial infarction, and unstable angina.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Effient, Prasugrel (discontinued: Prasugrel)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prasugrel hydrochloride
Tradename
Company
Number
Date
Products
EFFIENTCosette Pharmaceuticals N-022307 RX2009-07-10
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
effientNew Drug Application2022-09-07
prasugrelANDA2024-08-20
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC22: Prasugrel
HCPCS
Code
Description
G9531
Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
Clinical
Clinical Trials
256 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary artery diseaseD003324—I25.131016422291
Acute coronary syndromeD054058EFO_0005672—2818342484
Myocardial infarctionD009203EFO_0000612I211211251350
InfarctionD007238EFO_0009463—1211241349
SyndromeD013577——161120946
Myocardial ischemiaD017202EFO_1001375I20-I25254181341
Coronary diseaseD003327——243171338
St elevation myocardial infarctionD000072657———1712322
Cardiovascular diseasesD002318HP_0001626—12—8516
ThrombosisD013927————24713
Show 54 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D57221——5
PneumoniaD011014EFO_0003106———2——2
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.3——2——2
ThrombocytopeniaD013921HP_0001873D69.6——1——1
Thrombocytopenic purpuraD011696————1——1
PurpuraD011693HP_0000979D69.2——1——1
Coronary artery bypassD001026EFO_0003776———1——1
StentsD015607————1——1
NecrosisD009336————1——1
Renal dialysisD006435EFO_0010690Z99.2——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Critical illnessD016638———1———1
Respiratory tract diseasesD012140———1———1
Respiration disordersD012120—J00-J99—1———1
Aspirin-induced asthmaD055963HP_0012042——1———1
Lipid metabolism disordersD052439———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HivD006678——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Venous thrombosisD020246HP_0004936I82.40————44
Pulmonary embolismD011655HP_0002204I26————44
Blood platelet disordersD001791——————33
Arterial occlusive diseasesD001157EFO_0009085—————22
Heart valve prosthesisD006350EFO_0003906—————11
Chronic renal insufficiencyD051436—N18————11
Kidney diseasesD007674EFO_0003086N08————11
Cerebral hemorrhageD002543——————11
Subarachnoid hemorrhageD013345EFO_0000713I60————11
Nervous system diseasesD009422—G00-G99————11
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePrasugrel
INNprasugrel
Description
5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate is a member of the class of thienopyridines that is 2-acetoxy-4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the amino hydrogen is replaced by a 2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl group. It is an acetate ester, a member of cyclopropanes, a ketone, a member of monofluorobenzenes, a tertiary amino compound and a thienopyridine.
Classification
Small molecule
Drug classplatelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Identifiers
PDB—
CAS-ID1189919-49-0
RxCUI—
ChEMBL IDCHEMBL1201772
ChEBI ID87723
PubChem CID6918456
DrugBankDB06209
UNII ID34K66TBT99 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Effient – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Prasugrel
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,689 documents
View more details
Safety
Black-box Warning
Black-box warning for: Effient, Prasugrel
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
9,272 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use